Enveda Raises $311M to Advance Nature-Derived AI Drugs Into Clinical Trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the storyclinical trials
1 STORIESReporting and perspectives on clinical trials.